{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:30:09Z","timestamp":1793115009204,"version":"4.5.0"},"reference-count":35,"publisher":"American Academy of Pediatrics (AAP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,1]]},"abstract":"<jats:sec>\n                  <jats:title\/>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>BACKGROUND AND OBJECTIVES<\/jats:title>\n                  <jats:p>Although sickle cell disease (SCD)-related childhood mortality in the United States significantly improved in the 1990s, unclear is the trend in SCD-related mortality more recently given the continued disparities faced by this minoritized population. In this analysis, we aimed to (1) compare the overall and age-specific mortality rates from 1999 to 2009 vs 2010 to 2020 with a particular focus on the age of transition and (2) determine the most common causes of death for the US SCD population for 2010 to 2020.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>We analyzed publicly available data from the Centers for Disease Control and Prevention WONDER database, a compilation of national-level mortality statistics from 1979 to 2020 derived from death certificates compiled by the National Center for Health Statistics. We searched by all individuals of all ethnicities, sexes, and ages using the underlying cause of death.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>The crude mortality rate for individuals with SCD for 2010 to 2020 was 1.6 per 1\u2009000\u2009000 individuals, which was significantly lower than the period 1999 to 2009 (crude rate 1.7 per 1\u2009000\u2009000, P &amp;lt; .0001). In addition, the mean age at mortality of those with SCD was older in 2010 to 2020 (43 years) versus 1999 to 2009 (39 years). However, there remains a significant increase in mortality rate in the 20 to 24 year age group versus 15 to 19 years (1.7 per 1\u2009000\u2009000 versus 0.7 per 1\u2009000\u2009000, P &amp;lt; .0001), corresponding with the age of transition from pediatric to adult centers. In addition, 39% of underlying causes of death were not caused by SCD, but rather primarily chronic conditions, including cardiovascular, cerebrovascular, malignancy, and renal disease. The study has several limitations mostly because of the imperfections of administrative data sources, including inaccuracies in diagnoses codes, risking over or undercounting.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Although the US SCD-related mortality rate continues to decrease, the age of transition to adult care is a particularly vulnerable time in the lives of this marginalized group. Innovative and expanded approaches to care are greatly needed.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1542\/peds.2024-067341","type":"journal-article","created":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T08:06:34Z","timestamp":1731917194000},"source":"Crossref","is-referenced-by-count":23,"title":["Trends in Sickle Cell Disease Mortality: 1979\u20132020"],"prefix":"10.1542","volume":"154","author":[{"given":"Kristine A.","family":"Karkoska","sequence":"first","affiliation":[{"name":"aDivision of Hematology\/Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick T.","family":"McGann","sequence":"additional","affiliation":[{"name":"bDepartment of Pediatrics, Warren Alpert Medical School of Brown University, Providence, Rhode Island"},{"name":"cLifespan Comprehensive Sickle Cell Center at Hasbro Children\u2019s Hospital and Rhode Island Hospital, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2024,11,18]]},"reference":[{"key":"2024121614371911500_B1","doi-asserted-by":"crossref","first-page":"S512","DOI":"10.1016\/j.amepre.2009.12.022","article-title":"Population estimates of sickle cell disease in the U.S","volume":"38","author":"Hassell","year":"2010","journal-title":"Am J Prev Med"},{"issue":"23","key":"2024121614371911500_B2","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1056\/NEJM199406093302303","article-title":"Mortality in sickle cell disease. Life expectancy and risk factors for early death","volume":"330","author":"Platt","year":"1994","journal-title":"N Engl J Med"},{"issue":"1","key":"2024121614371911500_B3","doi-asserted-by":"crossref","first-page":"e28006","DOI":"10.1002\/pbc.28006","article-title":"Universal screening for social determinants of health in pediatric sickle cell disease: a quality-improvement initiative","volume":"67","author":"Power-Hays","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"2024121614371911500_B4","doi-asserted-by":"crossref","first-page":"248","DOI":"10.15585\/mmwr.mm7312a1","article-title":"Birth prevalence of sickle cell disease and county-level social vulnerability - sickle cell data collection program, 11 states, 2016\u20132020","volume":"73","author":"Kayle","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5","key":"2024121614371911500_B5","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jpainsymman.2014.02.002","article-title":"Perceived discrimination in health care is associated with a greater burden of pain in sickle cell disease","volume":"48","author":"Haywood","year":"2014","journal-title":"J Pain Symptom Manage"},{"issue":"4","key":"2024121614371911500_B6","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jpain.2022.11.004","article-title":"Depressive and insomnia symptoms sequentially mediate the association between racism-based discrimination in healthcare settings and clinical pain among adults with sickle cell disease","volume":"24","author":"McGill","year":"2023","journal-title":"J Pain"},{"key":"2024121614371911500_B7","first-page":"189","volume-title":"Sickle Cell Disease: Diagnosis, Management, Education, and Research","author":"Diggs","year":"1973"},{"issue":"6","key":"2024121614371911500_B8","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1542\/peds.81.6.749","article-title":"Newborn screening for sickle cell disease: effect on mortality","volume":"81","author":"Vichinsky","year":"1988","journal-title":"Pediatrics"},{"issue":"25","key":"2024121614371911500_B9","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1056\/NEJM198606193142501","article-title":"Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial","volume":"314","author":"Gaston","year":"1986","journal-title":"N Engl J Med"},{"issue":"9","key":"2024121614371911500_B10","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1001\/jama.1987.03400090089040","article-title":"Newborn screening for sickle cell disease and other hemoglobinopathies","volume":"258","author":"Consensus conference","year":"1987","journal-title":"JAMA"},{"issue":"11","key":"2024121614371911500_B11","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1086\/516781","article-title":"Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine","volume":"44","author":"Halasa","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"11","key":"2024121614371911500_B12","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1182\/blood-2003-11-3758","article-title":"Survival of children with sickle cell disease","volume":"103","author":"Quinn","year":"2004","journal-title":"Blood"},{"issue":"10","key":"2024121614371911500_B13","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/jama.2014.10517","article-title":"Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members","volume":"312","author":"Yawn","year":"2014","journal-title":"JAMA"},{"key":"2024121614371911500_B14","volume-title":"No. 02-2117 The Management of Sickle Cell Disease","author":"National Institutes of Health","year":"2002","edition":"Fourth Ed"},{"issue":"9","key":"2024121614371911500_B15","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1002\/pbc.24557","article-title":"Sickle cell disease related mortality in the United States (1999\u20132009)","volume":"60","author":"Hamideh","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"2024121614371911500_B16","first-page":"144","volume-title":"Vital Statistics: Summary of a Workshop","author":"Council","year":"2009"},{"key":"2024121614371911500_B17","volume-title":"R: A Language and Environment for Statistical Computing","year":"2022"},{"key":"2024121614371911500_B18","volume-title":"ggplot2: Elegant Graphics for Data Analysis","year":"2016"},{"issue":"10","key":"2024121614371911500_B19","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1093\/pm\/pnw074","article-title":"The opioid drug epidemic and sickle cell disease: guilt by association","volume":"17","author":"Ruta","year":"2016","journal-title":"Pain Med"},{"key":"2024121614371911500_B20","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1182\/blood-2023-189287","article-title":"Estimating sickle cell disease prevalence by state: a model using US-born and foreign-born state-specific population data","volume":"142","author":"Fu","year":"2023","journal-title":"Blood"},{"issue":"7","key":"2024121614371911500_B21","doi-asserted-by":"crossref","first-page":"e197613","DOI":"10.1001\/jamanetworkopen.2019.7613","article-title":"Hospital readmission of adolescents and young adults with complex chronic disease","volume":"2","author":"Dunbar","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"4","key":"2024121614371911500_B22","first-page":"CD009794","article-title":"Transition of care for adolescents from paediatric services to adult health services","volume":"4","author":"Campbell","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"2024121614371911500_B23","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s00467-017-3728-y","article-title":"Moving on: transitioning young people with chronic kidney disease to adult care","volume":"33","author":"Francis","year":"2018","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"2024121614371911500_B24","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.chc.2016.12.010","article-title":"Transition to adult health care services for young adults with chronic medical illness and psychiatric comorbidity","volume":"26","author":"McManus","year":"2017","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"issue":"6","key":"2024121614371911500_B25","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1136\/gutjnl-2016-313000","article-title":"UK guideline on transition of adolescent and young persons with chronic digestive diseases from paediatric to adult care","volume":"66","author":"Brooks","year":"2017","journal-title":"Gut"},{"issue":"6","key":"2024121614371911500_B26","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.blre.2013.09.001","article-title":"Management of sickle cell disease from childhood through adulthood","volume":"27","author":"Kanter","year":"2013","journal-title":"Blood Rev"},{"issue":"13","key":"2024121614371911500_B27","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1001\/jama.2010.378","article-title":"Acute care utilization and rehospitalizations for sickle cell disease","volume":"303","author":"Brousseau","year":"2010","journal-title":"JAMA"},{"issue":"9","key":"2024121614371911500_B28","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1007\/s00277-023-05365-5","article-title":"Age-related differences in risks and outcomes of 30-day readmission in adults with sickle cell disease","volume":"102","author":"Chen","year":"2023","journal-title":"Ann Hematol"},{"issue":"10","key":"2024121614371911500_B29","doi-asserted-by":"crossref","first-page":"e29209","DOI":"10.1002\/pbc.29209","article-title":"Transition care continuity promotes long-term retention in adult care among young adults with sickle cell disease","volume":"68","author":"Howell","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"2024121614371911500_B30","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.3390\/jcm8081154","article-title":"Shared care for adults with sickle cell disease: an analysis of care from eight health systems","volume":"8","author":"Mainous","year":"2019","journal-title":"J Clin Med"},{"key":"2024121614371911500_B31","doi-asserted-by":"crossref","first-page":"853835","DOI":"10.1155\/2015\/853835","article-title":"Attitudes toward management of sickle cell disease and its complications: a national survey of academic family physicians","volume":"2015","author":"Mainous","year":"2015","journal-title":"Anemia"},{"issue":"11","key":"2024121614371911500_B32","doi-asserted-by":"crossref","first-page":"e050880","DOI":"10.1136\/bmjopen-2021-050880","article-title":"Identifying barriers to evidence-based care for sickle cell disease: results from the Sickle Cell Disease Implementation Consortium cross-sectional survey of healthcare providers in the USA","volume":"11","author":"Smeltzer","year":"2021","journal-title":"BMJ Open"},{"key":"2024121614371911500_B33","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.annemergmed.2020.08.009","article-title":"Trends in sickle cell disease-related mortality in the United States, 1979 to 2017","volume":"76","author":"Payne","year":"2020","journal-title":"Ann Emerg Med"},{"issue":"3","key":"2024121614371911500_B34","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1182\/bloodadvances.2021005282","article-title":"GRNDaD: big data and sickle cell disease","volume":"6","author":"Lanzkron","year":"2022","journal-title":"Blood Adv"},{"issue":"23","key":"2024121614371911500_B35","doi-asserted-by":"crossref","first-page":"5429","DOI":"10.1182\/bloodadvances.2021005902","article-title":"ASH research collaborative: a real-world data infrastructure to support real-world evidence development and learning healthcare systems in hematology","volume":"5","author":"Wood","year":"2021","journal-title":"Blood Adv"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2024-067341\/1750393\/peds.2024-067341.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2024-067341\/1750393\/peds.2024-067341.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T14:38:56Z","timestamp":1734359936000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/154\/6\/e2024067341\/199887\/Trends-in-Sickle-Cell-Disease-Mortality-1979-2020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,18]]},"references-count":35,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,11,18]]},"published-print":{"date-parts":[[2024,12,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2024-067341","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,18]]},"article-number":"e2024067341"}}